The cost-effectiveness of radon-proof membranes in new homes: A case study from Brixworth, Northamptonshire, UK

Hughes JS. Ionising Radiation Exposure of the UK Population: 1999 Review. Report R311, National Radiological Protection Board Report. Chilton, UK: NRPB. Lubin, 1997, Lung cancer risk from residential radon: a meta-analysis of eight epidemiological studies, Journal of the National Cancer Institute, 89, 49, 10.1093/jnci/89.1.49 Denman, 1998, A review of the cost effectiveness of radon mitigation in domestic properties in Northamptonshire, Journal of Radiology Protection, 18, 119, 10.1088/0952-4746/18/2/007 Darby, 1998, Risk of lung lancer associated with residential radon exposure in South-West England: a case-control study, British Journal of Cancer, 78, 394, 10.1038/bjc.1998.506 Kreienbrock, 2001, Case–control study on lung-cancer and residential radon in Western Germany, American Journal of Epidemiology, 153, 42, 10.1093/aje/153.1.42 Darby, 2001, Radon: a likely carcinogen at all exposures, Annals of Oncology, 12, 1341, 10.1023/A:1012518223463 Darby, 2005, Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case–control studies, BMJ, 330, 223, 10.1136/bmj.38308.477650.63 Krewski, 2005, Residential radon and risk of lung cancer: a combined analysis of 7 North American case–control studies, Epidemiology, 16, 137, 10.1097/01.ede.0000152522.80261.e3 O’Riordan, 1990, Human exposure to radon in homes: recommendations for the practical application of the Board's statement, Documents of the NRPB, Chilton, UK, 1, 17 National Radiological Protection Board, 1993 Building Research Establishment (BRE). Radon: Guidance on Protective Measures for New Dwellings. BRE Report BR211 1992. Watford, UK. Building Research Establishment (BRE). Radon: Guidance on Protective Measures for New Dwellings 1999 Edition. BRE Report BR211 1999. Watford, UK. Denman, 2000, A comparison of the costs and benefits of radon remediation programmes in new and existing houses in Northamptonshire, Journal of Environmental Management, 59, 21, 10.1006/jema.1999.0331 Kennedy, 1999, A cost effectiveness analysis of a residential radon remediation programme in the United Kingdom, British Journal of Cancer, 81, 1243, 10.1038/sj.bjc.6690836 Coskeran, 2001, The cost of radon remediation in domestic properties, Health Policy, 57, 97, 10.1016/S0168-8510(00)00146-9 Coskeran, 2002, A critical comparison of the cost-effectiveness of domestic radon remediation programmes in three counties of England, Journal of Environmental Radioactivity, 62, 129, 10.1016/S0265-931X(01)00156-4 Stigum, 2003, Should radon be reduced in homes? A cost-effectiveness analysis, Health Physics, 84, 227, 10.1097/00004032-200302000-00011 Coskeran, 2005, A cost-effectiveness analysis of domestic radon remediation in four primary care trusts located in Northamptonshire, UK, Health Policy, 71, 43, 10.1016/j.healthpol.2004.05.003 Denman, 2005, Do radon-proof membranes reduce radon levels adequately in new houses? Groves-Kirkby, 2006, Radon mitigation in domestic properties and its health implications—a comparison between during-construction and post-construction radon reduction, Environment International, 32, 435, 10.1016/j.envint.2005.10.004 Green BMR, Miles JCH, Bradley EJ, Rees DM. Radon Atlas of England and Wales. National Radiological Protection Board Report W26, Didcot, UK, 2002. Sundal, 2004, The influence of geological factors on indoor concentrations of radon in Norway, Science of the Total Environment, 328, 41, 10.1016/j.scitotenv.2004.02.011 Sutherland, 1996, Radon—in Northamptonshire?, Geology Today, 12, 63, 10.1046/j.1365-2451.1996.00009.x Office for the Deputy Prime Minister, 2003 Wrixon AD, Green BMR, Lomas PR, Miles JCH, Cliff KD, Francis EA, et al. Natural radiation exposure in UK dwellings Report NRPB-R190. National Radiological Protection Board, Didcot, UK, 1988. Pinel, 1995, Seasonal correction factors for indoor radon measurements in the United Kingdom, Radiation Protection Dosimetry, 58, 127 Briggs, 2003, Time-activity modelling of domestic exposures to radon, Journal of Environmental Management, 67, 107, 10.1016/S0301-4797(02)00159-7 Miles, 1998, Radon-prone areas by lognormal modeling of house radon data, Health Physics, 74, 270, 10.1097/00004032-199803000-00010 Coskeran, 2006, A new methodology for cost-effectiveness studies of domestic radon remediation programmes: quality-adjusted life-years gained within Primary Care Trusts in Central England, Science of the Total Environment, 366, 32, 10.1016/j.scitotenv.2005.12.020 Trippoli, 2001, Quality of life and utility in patients with non-small cell lung cancer, Pharmacoeconomics, 19, 855, 10.2165/00019053-200119080-00007 Clegg, 2002, Clinical and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer: a systematic review, Thorax, 57, 20, 10.1136/thorax.57.1.20 Denman, 2003, Assessment of health risks to skin and lung from elevated levels in abandoned mines, Health Physics, 85, 733, 10.1097/00004032-200312000-00018 Warner, 1995, Effects of residential mobility on individual versus population risk of radon-related lung cancer, Environmental Health Perspectives, 103, 1144, 10.1289/ehp.951031144 Gold, 1996 Her Majesty's Treasury, 2003 Colgan, 1995, Justification and optimisation in the choice of reference levels for radon in existing Spanish dwellings, Journal of Radiological Protection, 15, 289, 10.1088/0952-4746/15/4/002 Kennedy, 2002, The cost-effectiveness of residential radon remediation programmes: assumptions about benefits stream profiles over time, Journal of Environmental Radioactivity, 59, 19, 10.1016/S0265-931X(01)00031-5 Committee on Health Risks of Exposure to Radon (BEIR VI), 1999 Stephens, 1974, EDF statistics for goodness of fit and some comparisons, Journal of the American Statistical Association, 69, 730, 10.2307/2286009 Mason, 1993, Some guidelines on the use of cost-effectiveness league tables, British Medical Journal, 306, 570, 10.1136/bmj.306.6877.570 Scuffman, 2004, An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK, Pharmacoeconomics, 22, 525, 10.2165/00019053-200422080-00004 Fiscella, 1996, Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians’ smoking cessation counseling, Journal of the American Medical Association, 275, 1247, 10.1001/jama.1996.03530400035035 Barr, 2004, Economic evaluation of treatments for cancer in childhood, European Journal of Cancer, 40, 1335, 10.1016/j.ejca.2004.01.033 Coskeran, 2005, The cost per quality adjusted life year gained of domestic radon remediation in four Northamptonshire Primary Care Trusts Marshall, 2001, Economic decision analysis model of screening for lung cancer, European Journal of Cancer, 37, 1759, 10.1016/S0959-8049(01)00205-2 Health Technology Assessment. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review, vol. 5, no. 13, 2001, 73 p. Health Technology Assessment. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review, vol. 5, no. 2, 2001, 97 p. Allsup, 2004, Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial, Vaccine, 23, 639 Raftery, 2001, NICE: faster access to modern treatments? Analysis of guidance on health technologies, British Medical Journal, 323, 1300, 10.1136/bmj.323.7324.1300 Williams A., What could be nicer than NICE? Office of Health Economics Annual Lecture; 2004. Baker R, Chilton S, Donaldson C, Jones-Lee M, Metcalf H, Shackley P, et al. Determining the Societal Value of a QALY by Surveying the Public in England and Wales: A Research Protocol. Submission to National Institute for Clinical Excellence and National Coordinating Centre for Research Methodology; 2003. Kip Viscusi, 1993, The value of risks to life and health, Journal of Economic Literature, 31, 1912 Ferrer-i-Carbonell, 2002, The subjective costs of health losses due to chronic diseases: an alternative model for monetary appraisal, Health Economics, 11, 709, 10.1002/hec.696 Hirth, 2000, Willingness to pay for a quality-adjusted life year: in search of a standard, Medical Decision Making, 20, 332, 10.1177/0272989X0002000310 Gyrd-Hansen, 2003, Willingness to pay for a QALY, Health Economics, 12, 1049, 10.1002/hec.799